id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4050	Dattola, Annunziata; Bernardini, Nicoletta; Caldarola, Giacomo; Coppola, Rosa; De Simone, Clara; Giordano, Domenico; Giunta, Alessandro; Moretta, Gaia; Pagnanelli, Gianluca; Panasiti, Vincenzo; Persechino, Severino; Potenza, Concetta; Trovato, Federica; Zangrilli, Arianna; Bianchi, Luca; Pellacani, Giovanni; Peris, Ketty; Richetta, Antonio Giovanni	Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region	2024	10	.pdf	application/pdf	5791	293	61	Anti-IL17 biologics drugs (including secukinumab, ixekizumab, brodalumab and bimekizumab) are effectice in Introduction: This was an observational, retrospective, multicenter study, enrolling elderly patients (>65 years old) treated with ixekizumab with a diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) during the period 2020 to 2023. Objectives: Efficacy of ixekizumab in elderly patients in the treatment of moderate to severe psoriasis. Objectives Our study was designed to evaluate, in a real-world setting, the effectiveness and safety of ixekizumab in elderly patients (>65 years old) with psoriasis (PsO) and/or psoriatic arthritis (PsA)	cache/dpc-4050.pdf	txt/dpc-4050.txt